ERN BOND patient representative – ePAGs

What are ePAGs?

European Patient Advocacy Groups (ePAGs) bring together patient representatives who collaborate and actively participate in the work of the European Reference Networks (ERNs).

ePAGs were established in collaboration with EURORDIS to promote strong patient involvement in decision-making and opinion-shaping processes across all ERNs. Each ERN is linked to a specific ePAG group, whose role is to embed the patient voice in the network’s activities.

Within ERN BOND, ePAG representatives speak on behalf of the wider rare bone disease community, ensuring that the needs and priorities of people living with rare bone diseases are reflected in the network’s strategic and operational work.

ePAG in ERN BOND

Patient representatives participate in all ERN BOND governance bodies, providing insight into the organisation and management of the network.

  • representing patients with rare bone diseases covered by ERN BOND and adhere to principles of equity within healthcare;
  • ensuring that clinical care recommendations are patient-centred and respect patients’ rights and choices;
  • promoting transparency;
  • monitoring ethical issues;
  • ensuring the evaluation of patient experience;
  • contributing to patient information, policy development, good practice, care pathways, and guidelines:
  • participating in ERN evaluation.

ERN BOND patient representatives

A total of eight patient advocates, representing eight different patient associations, are actively involved in ERN BOND’s activities.

Rebecca Tvedt Skarberg, lives in Oslo, Norway. Being born with osteogenesis imperfecta her interest in disability rights, equity and patient advocacy started from an early age. Her main goal has always been to spread awareness, knowledge and independency for people with rare conditions.
Rebecca is a trained social worker with additional degrees in psychology and counseling. She worked for the Norwegian National Welfare office (NAV) 2001 – 2014. Rebecca has worked for the Norwegian National Advisory Unit on Rare Disorders (NKSD) since 2014.

Rebecca has been engaged in international volunteer work through Osteogenesis Imperfecta Federation Europe (OIFE) and EURORDIS. In 2015 she contributed to the establishment of ERN BOND and was elected ePAG for ERN BOND in 2016. She has been a member of the steering committee in ERN BOND from the start and has also contributed in many of the working groups. She attended EURORDIS Leadership school of 2019. She has contributed to the establishment of the EuRR-Bone registry from 2020, especially working on patient involvement. She is on the advisory board for the Norwegian National registry for rare bone disorders. In 2019-2021 she served on the Rare2030 panel of experts. In 2021 she was awarded the Black Pearl volunteer award.

Inês Alves (DVM) has a degree in veterinary medicine, Oporto University, a post-graduation in soft tissues surgery, and is a Ph.D. student, Évora University, Portugal. Her advocacy involvement in rare bone conditions started after becoming the mother of a child with achondroplasia in 2012. She is member of the Committee for Orphan Medicinal Products (COMP) at the European Medicine Agency; ePAG and steering committee member in ERN BOND; founder and president of ANDO Portugal, the Skeletal Dysplasia National Association; co-leader of the Patient Outcomes at EuRR-Bone; EUPATI fellow and EUPATI Portugal vice-President; founder and first chair of the European Rare Bone Forum (ERBF); co-leader of the Translational Outreach working group of GEMSTONE COST action; member of EURORDIS E-rare and Rare2030 expert panel and a patient expert at EMA and IMI. One of her main interests is translational research in skeletal dysplasias and now, focusing on kinetics research in people with achondroplasia. ORCID ID: 0000-0001-8963-4736

Tenna Toft Sylvest was born in 1981 and lives in Copenhagen, Denmark with her husband and twin daughters. Tenna was diagnosed with X-linked Hypophosphatemia (XLH) at around 18 months as the first in her family. One of her twin daughters has inherited XLH. Tenna has a master’s degree in political science and works as a Senior IT Consultant in Denmark. In 2018 Tenna co-founded the Danish patient organisation for XLH where she has served as president since 2018. The Danish XLH organisation also includes patients with HPP. In 2017 Tenna helped establish the International XLH Alliance together with representatives from 5 other countries and currently serves as Co-Chair. Tenna has been a member of the ERN BOND ePAG group since 2019.

Liana is an Italian language teacher and is the parent of a patient with Multiple Osteochondromas. She beame involved with A.C.A.R. (the Italian Patient Association for Multiple Osteochondromas, Ollier disease and Maffucci syndrome) in 2017 and her role has focused on international relations through connecting with other Patients Associations throughout Europe and collaborating on networked initiatives.
The increasing importance of the patient voice remains especially important to her (given that she witnessed first hand the struggles that patients with these rare bone conditions face on a daily basis). In 2021, Liana was offered the opportunity to represent A.C.A.R. at the Post Graduate School of Health Economics and Management (ALTEMS), and study a Master’s degree in Patient Advocacy Management. An experience which has allowed her to further recognise the strategic value and importance of integrating the patient voice within the context of each stage of the medical research process.

Born in 1967 in Milan, Italy. Patient with achondroplasia, Marco Sessa is President since 2009 of Italian Association on Achondroplasia AISAC (Associazione per l’Informazione e lo studio dell’acondroplasia). He Degrees in 1994 in Political Science and work for 10 years as Strategic analyst for the energy sector. Since 2000 is Member of LEDHA Italian Association for the defence of right of people with disability. Writer, Blogger, in most important Italian Magazine on disabilities and on 3rd sector. Partner in VITA SPA (editor company of magazine VITA). Member in differents international Patients forum. He’s curios, and passionate in all activities is involved. His hobby are to read, to Sail, and to walk.

Nadine obtained her Master’s Degree in “Molecular Medicine” and continued her academic career as a Ph.D. candidate in Biochemistry with a focus on the rare disease Fibrodysplasia Ossificans Progressiva (FOP) and bone morphogenetic protein (BMP) signaling in an age-related context. She has a broad education in Molecular Biology, with a specific interest in understanding biomedical aspects of diseases. Moreover, Nadine is not only an FOP researcher but also lives with FOP and is in addition the vice-chair of the German FOP patient organization and a board member of the International FOP association’s board of directors. She is a highly active patient advocate who is determined to do everything she can to help find a cure for FOP.  She found her passion in raising as much awareness and funds as possible to educate people and identify the yet undiagnosed. In the recent past, the focus of her patient advocacy activities started to shift towards patient engagement and patient centricity.
Nadine is excited to contribute her expertise as both, a patient with FOP and an FOP researcher, which is a unique combination that empowers me to have a combined insight into both perspectives.

Claudia Finis is a psychologist and works as a research associate at the Berlin Institute of health at Charité in the field of rare diseases. In her work, she always combines the scientific and patient perspectives. She is active as a health policy representative for the German OI organisation (DOIG). Being born with OI she also represents patients at the Federal Joint Committee of Germany. She works at European and national level as a patient representative in the development of guidelines. As a women’s counsellor at the University of Dortmund for many years, it is important to her to always include the aspect of women’s health.

DOIG – Deutsche Gesellschaft für Osteogenesis imperfecta – Betroffene e.V.

Susana Noval Iruretagoyena has a degree in teaching and pedagogy, and is an expert in early stimulation and disabilities. She is the director of the ALPE Achondroplasia Foundation, a Spanish patient advocacy organization with an international scope.
Her interest in working on skeletal dysplasias began when a baby with achondroplasia was born in a very close family 27 years ago. Since then, she has worked in patient advocacy, first as a volunteer and later becoming ALPE team coordinator and later director. 
She is an expert in Medicines, research and development (Eurordis), ePAG (Eurordis), founding member of the European Skeletal Dysplasia Alliance, founding member of the Latin American Network of ASDD (Achondroplasia and other skeletal dysplasias with dwarfism), member of ICOSEP (International Coalition of Organizations Supporting Endocrine Patients) and  expert member of different advisory committees for the research of skeletal dysplasias.

Want to be an ePAG?

Applicants must meet the following criteria:

  • be a representative officially mandated by a national patient organisation for a rare bone disease, or a cluster of rare bone diseases, operating within Europe. For ultra-rare bone diseases for which no such organisation exists, an endorsement letter provided by a ERN BOND HCP member is accepted;
  • possess relevant experience or specific expertise from the patient perspective in rare bone diseases
  • knowledge of, or experience of living with, one of the rare and complex conditions included in the scope of ERN BOND;
  • willingness and motivation to get involved and contribute actively to the discussions and work of the ePAG and the ERN BOND working groups;
  • ability to work effectively and constructively with other patient representatives and clinicians from different EU countries;
  • ability to represent the interests of all the represented diseases under the scope of the ERN, beyond one’s own disease;
  • ability to provide an independent contribution from a patient representative perspective;
  • good communication skills in English (written and spoken).
  • work in partnership with other ePAGs, clinicians and researchers involved in ERN BOND;
  • contribute to the work and activities of ERN BOND;
  • ensure the diversity of views of the ERN BOND patient community, rather than representing your own disease area or personal experience;
  • support the ERN  in disseminating information, primarily to the patient community.
  • participate in at least two ERN BOND working packages (currently 8), selected based on personal interests, expertise and availability;
  • participate regularly in the majority of the ePAG calls;
  • report regularly in the ePAG calls and meetings on the progress of the work and projects in which;
  • participate in the ERN annual meetings, where possible – travel and accommodation expenses will be reimbursed subject to the ERN budgetary rules;
  • contribute to identifying and developing ERN BOND objectives and workplan;
  • contribute to the assessment of new applications for ePAG membership.
  • attend internal online ePAG calls approximately every two weeks, generally taking place in the afternoon and during working hours, no later than 19h CET;
  • attend online calls of work packages (on average one monthly online meeting of 1 hour, which takes place during working hours);
  • attend the ERN BOND annual meeting, which can be a full-day meeting or two half-day sessions;
  • dedicate time to reviewing and reading documents before or after meetings and calls;
  • undertake the role of ePAG secretary for a three-month period, with the responsibility for preparing the agenda and preparing the minutes for ePAGs internal meetings, as well as be responsible for communications. This is a rotating position between all ePAGs.
  • work closely with clinicians, researchers, and other patient representatives to transform healthcare services and accelerate research to improve health outcomes for people living with a rare bone disease in Europe;
  • participate firsthand in the development of the ERN objectives and infrastructure to ensure that it remains driven by patients’ needs;
  • increase international presence and expand international network, specifically across Europe;
  • improve understanding of healthcare models across Europe and European Reference Networks.

Application form

Before filling in the application form, prepare the following documents to upload:

  • A CV
  • A motivation letter explaining why you wish to join the ERN BOND ePAG
  • An endorsement from the patient organisation your represent. If the condition is ultra-rare and no patient organisation exists, an endorsement from an ERN BOND healthcare professional is accepted.

If you meet the criteria, your application will usually be followed by an interview before a final decision is made.

_______________

Application form from EURORDIS   – to check the questions asked https://form.jotform.com/211962393900355